Tuesday, October 15
CME/CE NOT APPLICABLE
One of the areas of greatest interest in current oncology practice is the use of genetic testing of poorly differentiated tumors, or tumors that are refractory to standard first and second line therapy, to identify the presence of mutations for which there is targeted chemotherapy. Much of the general excitement around the paradigm of so-called precision medicine (also known as personalized medicine or individualized therapy) revolves around the identification of these unexpected mutations, because it provides a rational approach to manage patients with few other treatment options. NGS provides the most cost-effective approach for the genetic analysis necessary to direct patient management in this clinical scenario, since the analysis requires the sequencing of large regions of one gene, or of multiple genes.
This talk will describe the practical issues that arise in the “real world” when NGS methods are used in routine practice to direct the care of cancer patients, including limitations in the quantity of tissue available for testing, changes in clinical practice that require analysis of different specimen types, and rapid changes in the sets of genes/types of mutations that are the targets of sequence analysis. This session will be especially useful to pathologists who are contemplating establishing NGS in their own practice but are uncertain of the pragmatic issues involved.
John D. Pfeifer, MD, PhD, FCAP